Johnson & Johnson Announces FDA Approval Of Invega Trinza

Janssen Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) approved under priority review the New Drug Application (NDA) for the three-month long-acting atypical antipsychotic INVEGA TRINZA. INVEGA TRINZA, a three-month injection, is an atypical antipsychotic indicated to treat schizophrenia. Before starting INVEGA TRINZA, patients must be adequately treated with INVEGA SUSTENNA (one-month paliperidone palmitate) for at least four months. It is anticipated that INVEGA TRINZA will be commercially available by the middle of June 2015.

In a long-term maintenance trial, 93 percent of patients treated with INVEGA TRINZA did not experience . . .